Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FBP1 | P09467 | 1/20 | 0.54 |
| ▸ | IGF2R | P11717 | 7/20 | 0.53 |
| ▸ | AMDHD2 | Q9Y303 | 1/20 | 0.47 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.46 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.46 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.46 |
| ▸ | AMY2A | P04746 | 3/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CD209 | Q9NNX6 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL941549 | 0.99 | FBP1 (0.55) | FBP1IGF2RAMDHD2LGALS8LGALS3 | |
| SCHEMBL8883425 | 0.99 | FBP1 (0.55) | FBP1IGF2RAMDHD2LGALS8LGALS3 | |
| SCHEMBL7541942 | 0.99 | FBP1 (0.55) | FBP1IGF2RAMDHD2LGALS8LGALS3 | |
| SCHEMBL16701297 | 0.97 | FBP1 (0.54) | FBP1IGF2RAMDHD2LGALS8LGALS3 | |
| SCHEMBL29397911 | 0.95 | IGF2R (0.50) | FBP1IGF2RAMDHD2LGALS8LGALS3 | |
| SCHEMBL30017785 | 0.92 | FBP1 (0.54) | FBP1IGF2RAMDHD2LGALS8LGALS3 | |
| SCHEMBL29941534 | 0.88 | FBP1 (0.53) | FBP1IGF2RAMDHD2LGALS8LGALS3 | |
| Cellobiose SCHEMBL21777654 | 0.88 | LGALS8 (0.52) | IGF2RLGALS8LGALS3LGALS4AMY2A | |
| Maltose SCHEMBL8343753 | 0.88 | LGALS8 (0.54) | IGF2RLGALS8LGALS3LGALS4AMY2A | |
| Cellobiose SCHEMBL11512625 | 0.88 | LGALS8 (0.54) | IGF2RLGALS8LGALS3LGALS4AMY2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8124124-B2 | Compressed tablet containing non-steroid antiinflammatory drug | RECKITT BENCKISER HEALTHCARE (UK) LIMITED (GB) | 2012-02-28 | — | — | US | disclosed |
| US-7771748-B2 | Pharmaceutical compositions of 5,7,14-triazatetracyclo[10.3.1.02,11.04,9]-hexadeca-2(11),3,5,7,9-pentaene | PFIZER INC (US) | 2010-08-10 | — | — | US | disclosed |
| CN-100346774-C | Treatment agent | BOOTS CO PLC (GB) | 2007-11-07 | — | — | CN | disclosed |
| EP-1448235-B1 | ORAL CONTROLLED RELEASE PHARMACEUTICAL COMPOSITIONS OF 5,8,14-TRIAZATETRACYCLO 10.3.1.0(2,11).0(4,9)]-HEXADECA-2(11)3,5,7,9-PENTAENE | PFIZER PROD INC (US) | 2007-03-14 | — | — | EP | disclosed |
| EP-1235558-B1 | COMPRESSED TABLET COMPOSITION COMPRISING A NSAID | BOOTS CO PLC (GB) | 2006-05-03 | — | — | EP | disclosed |
| EP-1448235-A1 | PHARMACEUTICAL COMPOSITIONS OF 5,7,14-TRIAZATETRACYCLO 10.3.1.0(2,11).0(4,9)]-HEXADECA-2(11)3,5,7,9-PENTAENE | Pfizer Products Inc. (US) | 2004-08-25 | — | — | EP | disclosed |
| EP-1080081-B1 | BENZOFUROXAN DERIVATIVES AND THEIR USE IN TREATING ANGINA PECTORIS | TORRENT PHARMACEUTICALS LTD (IN) | 2004-06-30 | — | — | EP | disclosed |
| US-20030203026-A1 | Therapeutic agents | RECKITT BENCKISER HEALTHCARE (UK) LIMITED (GB) | 2003-10-30 | — | — | US | disclosed |
| US-20030180360-A1 | Pharmaceutical compositions of 5,7,14-triazatetracyclo[10.3.1.02,11.04,9]-hexadeca-2 (11),3,5,7,9-pentaene | PFIZER INC. | 2003-09-25 | — | — | US | disclosed |
| CN-1433300-A | Treatment agent | BOOTS CO PLC (GB) | 2003-07-30 | — | — | CN | disclosed |
| US-6232331-B1 | TOLERANCE RESISTANT NITRIC OXIDE DONORS IN TREATMENT OF ANGINA PECTORIS | TORRENT PHARMACEUTICAL LTD. (IN) | 2001-05-15 | — | — | US | disclosed |
| EP-1080081-A1 | BENZOFUROXAN DERIVATIVES AND THEIR USE IN TREATING ANGINA PECTORIS | Torrent Pharmaceuticals Ltd (IN) | 2001-03-07 | — | — | EP | disclosed |
| EP-1079829-A1 | USE OF BENZOFUROXAN DERIVATIVES IN TREATING ANGINA PECTORIS | Torrent Pharmaceuticals Ltd (IN) | 2001-03-07 | — | — | EP | disclosed |
| WO-1999061018-A1 | USE OF BENZOFUROXAN DERIVATIVES IN TREATING ANGINA PECTORIS | SANKARANARAYANAN ALANGUDI (IN) | 1999-12-02 | — | — | WO | disclosed |
| WO-1999061430-A1 | BENZOFUROXAN DERIVATIVES AND THEIR USE IN TREATING ANGINA PECTORIS | SANKARANARAYANAN ALANGUDI (IN) | 1999-12-02 | — | — | WO | disclosed |
| US-5294644-A | Nonionic surfactants for solubility | ISP INVESTMENTS INC. (US) | 1994-03-15 | — | — | US | disclosed |
| US-5093031-A | Surface active lactams | ISP INVESTMENTS INC. (US) | 1992-03-03 | — | — | US | disclosed |
| EP-0311632-A4 | SURFACE ACTIVE LACTAMS | — | 1990-12-27 | — | — | EP | disclosed |
| EP-0311632-A1 | SURFACE ACTIVE LACTAMS. | GAF CORP (US) | 1989-04-19 | — | — | EP | disclosed |
| WO-1988000184-A1 | SURFACE ACTIVE LACTAMS | GAF CORPORATION (US) | 1988-01-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030180360-A1 | Pharmaceutical compositions of 5,7,14-triazatetracyclo[10.3.1.02,11.04,9]-hexadeca-2 (11),3,5,7,9-pentaene | CHRNA10, UGT1A10, CHRNA1 | FBP1 1729/4885IGF2R 974/4885AMDHD2 2902/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.